Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lee, Jong Gyu ^a   Ahn, Ji Hye ^a   Kim, Tae Jin ^b   Lee, Jae Ho ^b   Choi, Jung Hye ^a  

^a Kyung Hee University   (South Korea)

^b Dankook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA4 INTEGRIN; ITGB4 PROTEIN, HUMAN; PROTEIN KINASE B; PROTEIN P53; TP53 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; CELL ADHESION; EPITHELIUM; FEMALE; GENETICS; HUMAN; MCF-7 CELL LINE; METABOLISM; MISSENSE MUTATION; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; CELL ADHESION; EPITHELIUM; FEMALE; HUMANS; INTEGRIN BETA4; MCF-7 CELLS; MUTATION, MISSENSE; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84938521972     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12642     Document Type: Article

References (54)

1. Petitjean, A., Achatz, M. I., Borresen-Dale, A. L., Hainaut, P. & Olivier, M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157-2165 (2007).
2. Surwit, E. A. et al. Stage II carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 5, 323-326 (1979).
3. Dittmer, D. et al. Gain of function mutations in p53. Nat Genet 4, 42-46 (1993).
4. Solomon, H., Madar, S. & Rotter, V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. J Pathol 225, 475-478 (2011).
5. Oren, M. & Rotter, V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2, a001107 (2010).
6. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108 (2005).
7. Olivier, M., Hollstein, M. & Hainaut, P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2, a001008 (2010).
8. Rotter, V. p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proc Natl Acad Sci USA 80, 2613-2617 (1983).
9. Yaginuma, Y. & Westphal, H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52, 4196-4199 (1992).
10. Choi, J. H. et al. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res 68, 5716-5723 (2008).
11. Suzuki, N. et al. HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells. Gynecol Oncol 95, 290-298 (2004).
12. Brown, R. et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55, 678-684 (1993).
13. Debernardis, D. et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57, 870-874 (1997).
14. Legate, K. R., Wickstrom, S. A. & Fassler, R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev 23, 397-418 (2009).
15. Skubitz, A. P., Bast, R. C., Jr., Wayner, E. A., Letourneau, P. C. & Wilke, M. S. Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol 148, 1445-1461 (1996).
16. Choi, Y. P., Kim, B. G., Gao, M. Q., Kang, S. & Cho, N. H. Targeting ILK and beta4 integrin abrogates the invasive potential of ovarian cancer. Biochem Biophys Res Commun 427, 642-648 (2012).
17. Abdel-Ghany, M., Cheng, H. C., Elble, R. C. & Pauli, B. U. The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem 276, 25438-25446 (2001).
18. Laferriere, J., Houle, F. & Huot, J. Adhesion of HT-29 colon carcinoma cells to endothelial cells requires sequential events involving E-selectin and integrin beta4. Clin Exp Metastasis 21, 257-264 (2004).
19. Baril, P. et al. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene 26, 2082-2094 (2007).
20. Bon, G. et al. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. Cancer Res 69, 5978-5986 (2009).
21. Mitra, S. K. & Schlaepfer, D. D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18, 516-523 (2006).
22. Eliceiri, B. P. et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol 157, 149-160 (2002).
23. Lorusso, D. et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 14, 1086-1093 (2003).
24. Ayantunde, A. A. & Parsons, S. L. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18, 945-949 (2007).
25. Muller, P. A. et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 32, 1252-1265 (2013).
26. Bossi, G. et al. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 7, 1870-1879 (2008).
27. Murphy, K. L., Dennis, A. P. & Rosen, J. M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J 14, 2291-2302 (2000).
28. Duan, W., Gao, L., Jin, D., Otterson, G. A. & Villalona-Calero, M. A. Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice. Transgenic Res 17, 355-366 (2008).
29. Deb, D. et al. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants. Oncogene 21, 176-189 (2002).
30. Gualberto, A., Aldape, K., Kozakiewicz, K. & Tlsty, T. D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 95, 5166-5171 (1998).
31. Adorno, M. et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87-98 (2009).
32. Wang, S. P. et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 11, 694-704 (2009).
33. Dong, P., Xu, Z., Jia, N., Li, D. & Feng, Y. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Molecular Cancer 8, 103 (2009).
34. Yeudall, W. A. et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 33, 442-451 (2012).
35. Yoshikawa, K. et al. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomedical Research 31, 401-411 (2010).
36. Yeudall, W. A., Wrighton, K. H. & Deb, S. Mutant p53 in cell adhesion and motility. Methods Mol Biol 962, 135-146 (2013).
37. Feki, A. & Irminger-Finger, I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 52, 103-116 (2004).
38. Khromova, N. V., Kopnin, P. B., Stepanova, E. V., Agapova, L. S. & Kopnin, B. P. p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett 276, 143-151 (2009).
39. Song, H., Hollstein, M. & Xu, Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nature Cell Biology 9, 573-580 (2007).
40. Olivier, M., Hussain, S. P., Caron de Fromentel, C., Hainaut, P. & Harris, C. C. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 157, 247-270 (2004).
41. Cho, Y., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355 (1994).
42. Brosh, R. & Rotter, V. When mutants gain new powers: news from the mutant p53 field. Nature Review Cancer 9, 701-713 (2009).
43. Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687 (2002).
44. Lengyel, E. Ovarian cancer development and metastasis. Am J Pathol 177, 1053-1064 (2010).
45. Sawada, K. et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68, 2329-2339 (2008).
46. Slack-Davis, J. K., Atkins, K. A., Harrer, C., Hershey, E. D. & Conaway, M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 69, 1469-1476 (2009).
47. Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nature communications 4, 2126 (2013).
48. Beaufort, C. M. et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PloS one 9, e103988 (2014).
49. Monti, P. et al. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 22, 5252-5260 (2003).
50. Strano, S. et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277, 18817-18826 (2002).
51. Beviglia, L. & Kramer, R. H. HGF induces FAK activation and integrin-mediated adhesion in MTLn3 breast carcinoma cells. Int J Cancer 83, 640-649 (1999).
52. Matsuoka, T. et al. PI3K/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma. Br J Cancer 106, 1535-1542 (2012).
53. Oh, J. E., Kook, J. K. & Min, B. M. Beta ig-h3 induces keratinocyte differentiation via modulation of involucrin and transglutaminase expression through the integrin alpha3beta1 and the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 280, 21629-21637 (2005).
54. Huang da, W. et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8, R183 (2007).